PerkinElmer and Immunodiagnostic Systems have reached an agreement on the terms of an all-cash offer in which PerkinElmer will acquire IDS for approximately $155 million.
Headquartered in Boldon, the United Kingdom, IDS is an in-vitro diagnostic solution provider that develops, manufactures, and markets immunoassays and automated immuno-analyzer technologies. IDS’s immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. IDS has approximately 300 global employees.
Through the acquisition, PerkinElmer plans to grow its diagnostics business and combine its channel expertise and testing capabilities with IDS’s chemiluminescence products in endocrinology, autoimmunity and infectious diseases.
PerkinElmer expects to integrate IDS within EUROIMMUN.
The transaction has a total enterprise value of approximately $124 million and is expected to close early in the third quarter of 2021, subject to approvals from the shareholders of IDS, sanction by the High Court of Justice in England and Wales and other customary closing conditions for a public takeover in the United Kingdom.
